1. SGLT2 inhibitor improves CV outcomes in diabetic patients with chronic kidney disease
CANVAS programe subanalyses
HR (95%CI): 0.65 ( ) ( ) ( ) ( )
MACE: CV death, non-fatal myocardial infarction, or non-fatal stroke
SGLT2: Sodium glucose co-transporter 2; CV: cardiovascular; MACE: major adverse CV events; CANVAS: CANagliflozin cardio Vascular Assessment Study Program; eGFR: estimated glomerular filtration rate; T2D: type 2 diabetes; CKD: chronic kidney disease;
Neuen et al. Circulation 2018